Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
06/11/2013
06/11/2013
2012
|
Resumo |
Most of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather than in the setting of treatment interruption (TI). In this study, we analysed reasons given for TI and resistance mutations occurring in 150 HIV-1-infected patients who underwent TI. Of the patients analysed, 110 (73.3%) experienced TI following medical advice, while the remaining patients stopped antiretroviral therapy (ART) of their own accord. The main justifications for TI were: ARV-related toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI correlated with drug resistance (P < 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to this problem when the use of ARVs is interrupted. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2002/04016-4] |
Identificador |
INTERNATIONAL JOURNAL OF STD & AIDS, LONDON, v. 23, n. 2, pp. 120-125, FEB, 2012 0956-4624 http://www.producao.usp.br/handle/BDPI/42009 10.1258/ijsa.2011.011124 |
Idioma(s) |
eng |
Publicador |
ROYAL SOC MEDICINE PRESS LTD LONDON |
Relação |
INTERNATIONAL JOURNAL OF STD & AIDS |
Direitos |
restrictedAccess Copyright ROYAL SOC MEDICINE PRESS LTD |
Palavras-Chave | #HUMAN IMMUNODEFICIENCY VIRUS #HIV #ANTIRETROVIRAL THERAPY #RESISTANCE #TREATMENT INTERRUPTION #IMMUNODEFICIENCY-VIRUS TYPE-1 #BLOOD MONONUCLEAR-CELLS #REVERSE-TRANSCRIPTASE #INFECTED INDIVIDUALS #PROTEASE INHIBITORS #EXPERIENCED PATIENTS #RANDOMIZED-TRIAL #TREATMENT-NAIVE #MUTATIONS #PLASMA #IMMUNOLOGY #INFECTIOUS DISEASES |
Tipo |
article original article publishedVersion |